SUBSCRIBE
SUBSCRIBE
News   Drug Development

Myriad Genetics, Inc.'s Shares Fall on Continued Concern Over Prospects for Lead Drug Candidate

May 30, 2008 | 
1 min read
NEW YORK (AP) -- Shares of biotechnology company Myriad Genetics Inc. fell Wednesday on continued concern that the company's Alzheimer's disease drug candidate Flurizan could miss its goal in a late-stage study.
Clinical research Phase III
MORE ON THIS TOPIC
Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.
Friedreich’s ataxia
Larimar’s Friedreich’s Ataxia Drug Troubled by Anaphylaxis Concerns; Shares Fall
September 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration showing woman starting down curved path with markers toward goal marked by flag
Rare diseases
New Confirmatory Study Hints at ‘Alignment’ Between Applied Therapeutics, FDA for Rare Disease Drug
September 29, 2025
 · 
2 min read
 · 
Tristan Manalac
2D illustration of kidneys
Immunology and inflammation
Hansa Kidney Transplant Drug Aces Phase III Study, Headed to FDA
September 26, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of target and hands with the megaphone on a ue background with copy space. Concept of reaching a goal and spreading.
Pancreatic cancer
Immuneering Asset Nearly Doubles Overall Survival in Pancreatic Cancer After 9 Months
September 25, 2025
 · 
2 min read
 · 
Tristan Manalac